Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Discontinuation due to the high response rate at the 1st stage and slow accrual.

Conditions

Mayo Clinic